Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks -- Ignore unavailable to you. Want to Upgrade?

To: John Pitera who wrote (424)	3/1/2000 3:44:00 PM
From: IceShark	Read Replies (1) \| Respond to of 2850

Not many on MU either. Only a fool would short and the premiums on all are out of sight. Have to let 'em cool down a bit before there would be a chance of making much money. At this stage you would need them to get cut in half to make a double. -g- Smarter to sell options and hedge if one must.

To: John Pitera who wrote (424)	3/1/2000 7:05:00 PM
From: wlheatmoon	Read Replies (1) \| Respond to of 2850

Don't go out and buy all the shares at once..-g- Wednesday March 1, 7:58 am Eastern Time PE Corp offers 3.8 mln shrs of Celera Genomics ROCKVILLE, Md., March 1 (Reuters) - PE Corp. on Wednesday said it would offer 3.8 million shares of its Celera Genomics (NYSE:CRA - news) operating group at $225 a share in a follow-up public offering. Celera's net proceeds to Celera from the offering are expected to reach $820 million after fees. The company expects to use the offering's net proceeds to fund Celera's new products and technology development in genomics, the study of the function and structure of genes to develop drugs. Celera also intends to use the money generated by the offering for general corporate purposes, including possible acquisitions, alliances, or collaborations. The shares were offered by an underwriting group for which Morgan Stanley Dean Witter, Goldman, Sachs & Co., SG Cowen, ING Barings, and Bear Stearns & Co., acted as representatives. The underwriters also have an option to purchase up to an additional 570,000 shares of Celera Genomics common stock to cover over-allotments. PE Corp comprises two operating groups. Celera Genomics Group, headquartered in Rockville, Md., and PE Biosystems Group (NYSE:PEB - news), headquartered in Foster City, Calif. which develops and markets instrument-based systems, software, and contract related services to the life science industry.